Drug Trial Radar · NCT05239728
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
Last checked: Nov 20, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,800
Planned (sponsor's estimate)
Start
Mar 15, 2022
Primary completion
Oct 28, 2026
Study completion Sep 28, 2029
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 15, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary study hypothesis is that belzutifan plus pembrolizumab is superior to placebo plus pembrolizumab with respect to disease-free survival (DFS).
Conditions
- Carcinoma, Renal Cell
Interventions
BelzutifanDrug
Three 40 mg tablets given as a single oral 120 mg dose.
PembrolizumabBiological
400 mg via IV infusion
PlaceboDrug
Oral tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Disease-Free Survival (DFS)Time frame: Up to approximately 54 months
Locations
285 sites in 32 countries. Site status is shown where the registry gives one.
Mayo Clinic in Arizona - Phoenix ( Site 3554)
Phoenix, Arizona
City of Hope Comprehensive Cancer Center ( Site 3567)
Duarte, California
Moores Cancer Center-Clinical Trials Office- Genitourinary ( Site 3516)
La Jolla, California
UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 3520)
Los Angeles, California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3518)
Orange, California
Stanford Cancer Center ( Site 3523)
Palo Alto, California
University of Colorado Anschutz Medical Campus ( Site 3514)
Aurora, Colorado
Intermountain Health St. Mary's Regional Hospital ( Site 3562)
Grand Junction, Colorado
Georgetown University Medical Center ( Site 3534)
Washington D.C., District of Columbia
University of Miami Hospital and Clinics, Sylvester Cancer Center-Cancer Research Services ( Site 3517)
Miami, Florida
Moffitt Cancer Center ( Site 3540)
Tampa, Florida
Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 3515)
Marietta, Georgia
Parkview Research Center at Parkview Regional Medical Center ( Site 3526)
Fort Wayne, Indiana
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center- GU Oncology ( Site 3549)
Baltimore, Maryland
Massachusetts General Hospital ( Site 3571)
Boston, Massachusetts
Beth Israel Deaconess Medical Center-Cancer Clinical Trials Office ( Site 3572)
Boston, Massachusetts
Dana-Farber Cancer Institute-GU ( Site 3505)
Boston, Massachusetts
Cancer and Hematology Centers of Western Michigan ( Site 3502)
Grand Rapids, Michigan
Washington University-Internal Medicine/Oncology ( Site 3531)
St Louis, Missouri
St. Vincent Frontier Cancer Center-Research ( Site 3506)
Billings, Montana
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 3550)
Omaha, Nebraska
Englewood Hospital and Medical Center ( Site 3557)
Englewood, New Jersey
Rutgers Cancer Institute of New Jersey ( Site 3541)
New Brunswick, New Jersey
Monter Cancer Center ( Site 3560)
Lake Success, New York
Icahn School of Medicine at Mount Sinai ( Site 3539)
New York, New York
Memorial Sloan Kettering Cancer Center ( Site 3568)
New York, New York
University of Rochester Medical Center ( Site 3528)
Rochester, New York
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 3507)
Columbus, Ohio
MidLantic urology ( Site 3501)
Bala-Cynwyd, Pennsylvania
Fox Chase Cancer Center-GU Oncology ( Site 3535)
Philadelphia, Pennsylvania
Sanford Cancer Center ( Site 3551)
Sioux Falls, South Dakota
The West Clinic, PLLC dba West Cancer Center ( Site 3522)
Germantown, Tennessee
Urology Associates ( Site 3512)
Nashville, Tennessee
UT Southwestern Medical Center ( Site 3529)
Dallas, Texas
University of Texas MD Anderson Cancer Center-Urology ( Site 3569)
Houston, Texas
Inova Schar Cancer Institute ( Site 3525)
Fairfax, Virginia
Seattle Cancer Care Alliance-Renal/Melanoma/MCC ( Site 3524)
Seattle, Washington
Blacktown Hospital ( Site 0002)
Blacktown, New South Wales, Australia
Macquarie University-MQ Health Clinical Trials Unit ( Site 0003)
Macquarie University, New South Wales, Australia
Tamworth Hospital-North West Cancer Centre ( Site 0006)
North Tamworth, New South Wales, Australia
Showing 40 of 285 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.